This site is intended for health professionals only
Content funded and provided by GSK
For healthcare professionals only
Prescribing information is available via a link at the bottom of the page
LAMA/LABAs are indicated as maintenance bronchodilator treatments to relieve symptoms in adult patients with COPD.
NICE updated its COPD guideline (in Dec 2018) to recommend LAMA/LABA as initial maintenance therapy in patients with no asthmatic features/features suggesting steroid responsiveness who remain breathless/have exacerbations despite short acting bronchodilator therapy.1
According to the guidance, such patients should have spirometrically confirmed COPD as well as have been offered/received treatment for tobacco dependence (if smokers), had optimised non-pharmacological management and received relevant vaccinations.1
The NICE guidelines state that ‘the evidence showed that, compared with other dual therapy combinations and monotherapy, LAMA+LABA’:1
© NICE 2019 Chronic obstructive pulmonary disease in over 16s: non-pharmacological management and use of inhaled therapies. Available from
www.nice.org.uk/guidance/NG115 All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication. For more information on the NICE COPD guidelines see www.nice.org.uk/guidance/NG115.
GSK organised and funded a roundtable meeting with respiratory experts to discuss the health-system impact of LAMA/LABA initial maintenance therapy (IMT) in COPD. Attendees were paid an honorarium for their time by GSK. Watch the video to understand why you might want to consider LAMA/LABA initial maintenance therapy (IMT) in specific COPD patients.
Watch more expert perspectives videos
Anoro▼Ellipta (umeclidinium/vilanterol) has head-to-head data vs. tiotropium HandiHaler1-4 (a LAMA) and vs. Spiolto Respimat & Bevespi Aerosphere (other LAMA/LABAs).2,3
Explore the differences and discover more about Anoro now.
Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.
Adverse events should be reported. Reporting forms and information can be found
at yellowcard.mhra.gov.uk or search for MHRA Yellow card in the Google Play or Apple App store.
Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
PM-GB-UCV-WCNT-200007 V5.0 | May 2022
© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
Anoro Ellipta was developed in collaboration with Innoviva.
